Therapeutics: Serine/arginine-rich splicing factor 2 (SRSF2); splicing factor 3B subunit 1 (SF3B1)

Cancer

INDICATION: Acute myelogenous leukemia (AML)

Mouse studies suggest inhibiting SF3B1 could help treat SRSF2-mutant AML.

Read the full 145 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE